期刊文献+

α7尼古丁受体基因抑制对SH-SY5Y细胞α-分泌酶水平的影响

Influence of inhibited α7 nicotinic acetylcholine receptor gene expression on level of α-secretase in SH-SY5Y Cells
下载PDF
导出
摘要 目的采用RNA干扰技术抑制神经母细胞瘤细胞(SH-SY5Y细胞)中α7神经型尼古丁乙酰胆碱受体(Neuronal nicotinic acetylcholine receptor,nAChR)基因表达,了解对APP代谢中的关键酶α-分泌酶水平的影响。方法 SH-SY5Y细胞转染针对α7 nAChR的小干扰RNA(small interference RNA,siRNA),用Real-time PCR法和Western blotting法分别测定细胞中α7 nAChR、α-分泌酶(ADAM10)在mRNA和蛋白表达水平的变化。结果转染α7 nAChR siRNA后,与对照组相比,α7 nAChR mRNA及蛋白表达水平明显降低;ADAM10mRNA及蛋白表达水平分别减少了73%和66%。结论α7 nAChR基因表达抑制后α-分泌酶水平明显降低,这种改变可能与α7 nAChR基因表达抑制后β-淀粉样蛋白(Aβ)的产生增多有关,可能与阿尔茨海默病(AD)的发病有一定的关系。 Objective To investigate the influence of inhibited α7 neuronal nicotinic acetylcholine receptor(nAChR)by small interference RNA(siRNA)on the level of α-secratase,the key enzyme in APP metabolism,in SH-SY5Y cells.Method The siRNA of α7 nAChR was transfected into SH-SY5Y cells,and the expressions of α7 nAChR and α-secretases(ADAM10)at mRNA and protein levels were studied by real-time PCR and Western blotting,respectively.Result As compared with controls,the expression of α7 nAChR at mRNA and protein levels in the SH-SY5Y cells transfected with the α7 nAChR siRNA were decreased significnatly.The expressions of ADAM10 were decreased by 73%and 66%,respectively.Conclusion The inhibited α7 nAChR mRNA induced by siRNA may obviously decrease the level of α-secretase which may connected to the increased production of Aβ induced by the inhibiting of α7 nAChR,and might be connnected to the pathogenesis of AD.
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2012年第11期968-970,共3页 Journal of Apoplexy and Nervous Diseases
基金 国家自然科学基金资助项目(30960123) 贵州省科技厅基金项目黔科合J字2010[3140]
关键词 α7尼古丁乙酰胆碱受体 Α-分泌酶 阿尔茨海默病 α7 nAChR α-secretase Alzheimer's disease
  • 相关文献

参考文献11

  • 1Osbom GG. Current treatments for patients with Alzheimer disease [ J]. Am Osteopath Assoe ,2010,110( Suppl 8 ) : S16 - 26.
  • 2官志忠,齐晓岚.阿尔茨海默病的分子发病机制及其治疗研究进展[J].中华病理学杂志,2008,37(1):11-15. 被引量:38
  • 3Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer' s disease : progress and problems on the road to therapeutics[ J ]. Science,2002, 297 (5580) :353 - 356.
  • 4Postina R. A closer look at ct-secretase[ J]. Curt Alzheimer Res, 2008,5(2) :179 - 186.
  • 5Higashitani A, Hashizurne T, Sugimoto T, et al. C. elegans RNAi space experiment ( CERISE ) in Japanese Experiment Module KIBO [J]. Biol Sci Space,2009,23(4) :183 -187.
  • 6Xie Z, Wroblewska L, Prochazka L, et al. Multi-input RNAi-based logic circuit for identification of specific cancer cells [ J]. Science, 2011,353(6047) :1307 - 1311.
  • 7Toyohara J, Hashimoto K. eL7 Nicotnic Receptor Agonists : Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizo- phrenia and Alzheimer' s Disease [ J]. Open Med Chem J,2010,4 : 37 - 56.
  • 8Nordberg A. Nicotinic receptor abnormalities of Alzheimer' s disease : therapeutic implications[ J]. Biol Psychiatry,2001,49:200 - 210.
  • 9D' Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcho- line receptor to reduce amyloid accumulation in Alzheimer' s disease pyramidal neurons [ J ]. Curt Pharm Des,2006,12 ( 6 ) :677 - 684.
  • 10Schroeder A, Fahrenholz F, Schmitt U. Effect of a dominant-negative form of ADAMIO in a mouse model of Alzheimer' s disease [ J ]. Alzheimers Dis,2009,16(2) :309 -314.

二级参考文献1

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部